Activating Akt by deletion of PTEN or by Myr-Akt (constitutively active Akt) expression has been shown to increase tumor incidence, accelerate tumor onset, and elevate tumor malignancy in multiple mouse glioma models [17,18]. The gene discussed is AKT1; the disease is glioma.